Evidence map›Paper›PMID 25988120›Full record

ReviewFrontiers in nutrition2014

Hydroxytyrosol and potential uses in cardiovascular diseases, cancer, and AIDS.

Cristina Vilaplana-Pérez, David Auñón, Libia A García-Flores, Angel Gil-Izquierdo

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in nutrition, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
72citing papers in PubMed, 2 pooled it
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

72 citing papers in PubMed, 2 syntheses or guidelines pooled it, 140 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. The Phenolic Signature ofFood science & nutrition · 2025
    Article
  17. Article
  18. Article
  19. Article
  20. Review

12 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Cristina Vilaplana-PérezDepartment of Food Science and Technology, Centro de Edafología y Biología Aplicada del Segura, CSIC , Murcia , Spain.
David AuñónDepartment of Research and Development, Seprox BIOTECH, S.L. , Madrid , Spain.
Libia A García-FloresDepartment of Food Science and Technology, Centro de Edafología y Biología Aplicada del Segura, CSIC , Murcia , Spain.
Angel Gil-IzquierdoDepartment of Food Science and Technology, Centro de Edafología y Biología Aplicada del Segura, CSIC , Murcia , Spain.
Centro de Edafología y Biología Aplicada del Segura · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hydroxytyrosol is one of the main phenolic components of olive oil. It is present in the fruit and leaf of the olive (Olea europaea L.). During the past decades, it has been well documented that this phenolic compound has health benefits and a protective action has been found in preclinical studies against several diseases. Here, we review its bioavailability in human beings and several assays showing significant results related with cardiovascular diseases, cancer, and acquired immunodeficiency syndrome (AIDS). Mechanisms of action include potent anti-oxidant and anti-inflammatory effects, among others. The importance of hydroxytyrosol in protection of low-density lipoproteins and consequently its implication in the reduction of cardiovascular disease risk has been highlighted by the European Food Safety Authority, concluding that 5 mg of hydroxytyrosol and its derivatives should be consumed daily to reach this effect at physiological level. We discuss the potential uses of this compound in supplements, nutraceutic foods, or topical formulations in the disease risk reduction. Finally, we conclude that more studies are needed to sustain or reject many other health claims not yet fully documented and to validate these newly available hydroxytyrosol-based products, because it seems to be a good candidate to reduce the risk of diseases mentioned.

Indexed as

anti-oxidantsdiseasehydroxytyrosololive oilphenolic compounds

Identifiers

PMID25988120
PMCPMC4428486
OpenAlexW2022783062

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.